Antibodies and related molecules that bind to PSCA proteins

US8013128B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Jean Gudas · Los Angeles, US
• Aya Jakobovits · Beverly Hills, US
• Xiao-Chi Jia · Los Angeles, US
• Robert Kendall Morrison · Santa Monica, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Hui Shao · Indianapolis, US
• Pia M. Challita-Eid · Calabasas, US
• Arthur B. Raitano · Los Angeles, US

Key dates

• Filing date: Mar 4, 2009
• Grant date: Sep 6, 2011
• Expiry date: Jul 18, 2029

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.